Back

FDA expedited access pathway enables staged approval opportunity for baroreflex activation therapy for heart failure with reduced ejection fraction: the BeAT-HF trial

21 May 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Devices / CRT / ICD Devices and technology HFA Premium Access HEART FAILURE 2016

About the speaker

Photo
Professor William Abraham

The Ohio State University, Columbus (United States of America)

22 More presentations in this session

Presentation thumbnail
Could one-year effect of cardiac resynchronization therapy on hemodynamic parameters evaluated by impedance cardiography be predicted ?
Mr M. Orszulak (Katowice, PL)
Abstract
Presentation thumbnail
A local network for refractory cardiogenic shock
Doctor C. Sorini Dini (Siena, IT)
Abstract Slides
Presentation thumbnail
Long-term survival and predictors of mortality in patients supported with a left ventricular assist device as destination therapy
Doctor C. Kapelios (Athens, GR)
Abstract Slides
Presentation thumbnail
Single center long term results of mechanical circulatory support in the netherlands
Doctor N. de Jonge (Utrecht, NL)
Abstract
Presentation thumbnail
Soluble ST2 levels in end-stage heart failure and during LVAD support
Doctor N. de Jonge (Utrecht, NL)
Abstract

Access the full session

Session thumbnail
Poster Session 3 - Devices / CRT / ICD

The Event

Event poster

HEART FAILURE 2016

21 May - 24 May 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources